Tag: SOPHiA GENETICS
-
SOPHiA GENETICS Reports 2025 Results, Sets 2026 Guidance, and Announces CEO Transition
Strong Q4 2025 Performance and Full-Year Results SOPHiA GENETICS, a global leader in AI-driven precision medicine, announced preliminary fourth-quarter and full-year 2025 financial results, highlighting robust momentum as the company advances its AI-powered platform across life sciences and clinical applications. While the company noted that the 2025 results are preliminary, management emphasized solid quarterly execution…
-
SOPHiA GENETICS Announces 2025 Results, 2026 Guidance, and CEO Transition Plan
Executive Summary: Strong 2025 Close and New Growth Outlook SOPHiA GENETICS (Nasdaq: SOPH) has disclosed preliminary fourth-quarter and full-year 2025 financial results, along with guidance for 2026 and a strategic executive transition. The company underscored a solid close to 2025, highlighted by robust Q4 performance, and introduced its 2026 revenue growth target of 20-22%. In…
-
SOPHiA GENETICS Reports Strong Q4 2025, Sets 2026 Growth Path and Names New CEO
SOPHiA GENETICS Announces Strong Q4 2025 Performance and Full-Year Results SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI-driven genomic analytics, released preliminary fourth-quarter and full-year 2025 results that underscore the company’s momentum as it navigates a competitive bioinformatics landscape. While the company provided preliminary numbers ahead of final audited results, executives highlighted continued revenue growth,…